AiCuris names Larry Edwards as CEO and president of new US subsidiary
Wuppertal, Germany-based infectious disease drug developer AiCuris Anti-infective Cures today announced the appointment of Larry Edwards as chief executive (CEO), effective April 1, 2023.
Mr Edwards is an experienced executive with a strong track record of financing and building net cash positive biopharmaceutical companies, as well as successful M&A. He joins with excellent leadership capabilities and will be responsible for driving AiCuris’ growth strategy as well as managing its overall operations.
Prior to joining AiCuris, Mr Edwards served as president and CEO of publicly traded La Jolla Pharmaceuticals, which he successfully sold and integrated into Innoviva.. Before that, he was CEO of Tetraphase Pharmaceuticals, which was acquired by La Jolla in 2020. Prior to that he worked for Cubist Pharmaceuticals and Merck & Co (NYSE: MRK) for over 16 years, in a variety of global and US commercial and leadership roles with escalating responsibilities.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze